Arterra Bioscience Spa · MIL:ARBS
Arterra Bioscience Spa — Spring Investor Conference 2025, Milan (Banca Profilo)
24 slides from Arterra Bioscience Spa's conference presentation, Apr 2, 2025
Slide 1: Spring Investor Conference Milan
Spring Investor Conference Milan Banca Profilo April 2nd, 2025
Slide 2: Index
Index TOPICS • ARTERRA AT GLANCE • MARKET CONSOLIDATION & DIVERSIFICATION • FINANCIALS
Slide 3: People Speaking Today
People Speaking Today M. GABRIELLA COLUCCI GUALTIERO IOIMO Founder, President and CEO CFO and Investor Relations Manager
Slide 4: Arterra Bioscience - Innovative SME
Arterra Bioscience - Innovative SME Arterra Bioscience Is a biotech company listed on the “Euronext Growth Milan” market of Borsa Italiana since 2019, founded in Naples by M. Gabriella Colucci in 2004 with the aim of developing technologies and innovative solutions that find application in various i
Slide 5: Arterra Organization
ARTERRA ORGANIZATION Spring Investor Conference Milan Banca Profilo April 2 nd, 2025
Slide 6: Arterra & Vitalab Team
Arterra & Vitalab Team 32 10 PhD 13 Chem Ing 1 MSc 9 Tech 11 Administration 6 PhD Students 2 1256 Sqm
Slide 7: Our facilities
Our facilities Chemistry Lab Plant Cell Culture Lab Microbiology Lab Molecular & Cell Biol. Lab Histology & Microscopy Lab Production Lab Plant Cells Culture Growing Facility MicroAlgae Growing Facility Plant Growing Facility Lactobacillus Growing Facility
Slide 8: Scientific Management team
Scientific Management team MARIDA BIMONTE MAURA ANGELILLO M. GABRIELLA COLUCCI VINCENZO FOGLIANO Grant & IP 23& Sales Marketing CEO CSO Director Manager GUALTIERO IOIMO GIUSEPPE FERRANTE ANNALISA TITO CFO & Investor COO Cell & Mol Biol. Director Relations Manager
Slide 9: Company organization
Company organization President & CEO Gabriella Colucci CFO and Investor Relations Manager Chief Operating Officer Gualtiero Ioimo Giuseppe Ferrante Cell Colture PTS Opt Quality Control Chief Scientific Officer Extraction & PF Luigi Sena Vincenzo Fogliano PTS Val Logistic Vitalab: Marketing Sales & C
Slide 10: Arterra position in relevant markets
Arterra position in relevant markets Ingredients for: Ingredients for: Consumer cosmetics Beauty Cosmetics Skin Care, Make-Up, Personal Cair & Professional Cosmetic Products for topical Hair Care applications in Aestetic Medicine consolidated market through Intercos & New segment of a known market V
Slide 11: Innovation in COSMETICS
Innovation in COSMETICS CONSOLIDATED SEGMENT: SKIN CARE & MAKE-UP & HAIRCARE 2024/2025 Tito A, et All. Skin rejuvenating properties of a powerful blend of Gardenia jasminoides peptides and flavonoids.HPC Today, 1/2024. PCT/EP2024/074175. Use of plant-derived extracts for hair growth Di Lorenzo R, et
Slide 12: Innovation in COSMETICS - New products on the market
Innovation in COSMETICS 8 New products on the market Vita Gly-Jasmine Cordys Revitagen Vita D-Light Vita RisePeptides Jasminum Sambac Cordyceps sinensis Corthellus shiitake Hydrolyzed Rice Bran Plant cell extract extract extract Extract Vita PeptiBloom Vita NiaCeraMine PlantExo Vita Vita TechCollage
Slide 13: Regulatory Achievements
Regulatory Achievements China State Council released the final version of CSAR on 01 January 2021 and replaced the existing Cosmetics Hygiene Supervision Regulations China’s new cosmetics regulation include many changes: New cosmetic definitions, scope and classifications Management of new cosmetic
Slide 14: Innovation in COSMETICS started in 2023
Innovation in COSMETICS started in 2023 Powder active ingredients for make- CC market in up application 2025 Recombinant peptides using molecular CME CC market in market in farming technology* 2025 2025 Post-Biotics using precision CC fermentation Technology market CME CC Extracellular Vescicles EV
Slide 15: Exosomes: The new wave Opportunity
EXOSOMES: The new wave «Opportunity» Source: Graça Raposo, Willem Stoorvogel, JCB Feb 18,2013 Exosomes and EVs are extracellular vesicles released by all cells (eukaryotic or prokaryotic) having a number of complex biological funtions. o They are surrounded by a lipidic membrane protecting their car
Slide 16: Plant Exosomes in professional beauty treatments
Plant Exosomes in professional beauty treatments t Source: Zhang B, Gong J, He L, Khan A, Xiong T, Shen H and Li Z (2022). Exosomes based advancements for application in medical aesthetics. Front. Bioeng. Biotechnol. 10:1083640. doi: 10.3389/fbioe.2022.1083640
Slide 17: Key company highlights
More Focus on exosomes innovation with Longevity Longevity is a new company dedicated to advancing exosome-based solutions for cosmetics and aesthetic medicine. Key company highlights • Biotech based technology for high quality reproducibility and safety. • Proprietary isolation method for superior
Slide 18: Our Exosome
Our Exosome Insolated from sterile grown cell culture and in liquid sterile grown microgreens Clean & Bio CME market in CC market in • No Biological contamination 2025 2025 • No chemical contaminattion • Never exposed to environmental pollution • Standardized conditions: no variability due to coltiv
Slide 19: The Beauty of Biotech: ONE for MANY
The Beauty of Biotech: ONE for MANY Arterra + Vitalab + Longevity In giving value to bio-knowledge Cell Culture Biomass 2 kg PF Hydrosoluble + 2 kg PF Liposoluble CC market in 200 gr Or 500 ml 1 kg PF CC CME market market Cell Culture MultiPeptides in in 2025 1 week Or PDRN CC CME (Polydeoxyribonucl
Slide 20: Financials
FINANCIALS Spring Investor Conference Milan Banca Profilo April 2 nd, 2025
Slide 21: Economic results as of December 31, 2024
32,15% Economic results as of December 31, 2024 Value of Production (€/000) Ebitda (€/000) Net Income (€/000) 2500 40,2% 26,7% 5.303 5.266 25,4% 4.951 35 2.133 1,414 498 32,5% 21,7% 1,337 231 2000 1,058 32,1% 1.712 1,076 1,242 1.591 1,416 1500 1000 4,173 3,564 3,304 500 2022 2023 2024 0 2022 2023 20
Slide 22: Net Debt / Equity
Net Debt / Equity Net Debt (€/000) Equity (€/000) 11,423 2022 2023 2024 Cash and Cash Equivalents (4.393) (3.686) (3.343) 10,751 10,467 Current Financial Receivables - - - 891 Financial assets other 1.823 than fixed assets (1.598) Current Financial Debt 174 86 96 Current Net Debt (5.817) (3.599) (3.
Slide 23: Difference between 2024 and 2023
Difference between 2024 and 2023 €4,500.00 €4,172.90 +28 €4,000.00 % The total turnover has increased by 28%. €3,519.14 €3,500.00 +34 % €3,254.75 The main difference between the 2024 and €3,000.00 the 2023 is the sale of raw materials, €2,632.67 €2,500.00 which has increased by 34%. €2,000.00 Additi
Slide 24: Thank You!
Spring Investor Conference Milan Banca Profilo THANK YOU!
Arterra Bioscience — Spring Investor Conference 2025, Milan (Banca Profilo) on 6ix